Abstract 195P
Background
Ferroptosis is a type of programmed cell death dependent on iron metabolism distinct from necrosis and apoptosis. In pancreatic ductal adenocarcinomas (PDAC), studies have noted that ferroptosis signatures are also associated with survival. However, no studies have attempted to find histological correlates which might suggest a ferroptosis process occurring.
Methods
PDACs from the Cancer Genome Atlas (TCGA) Pan-Cancer were used. Clinicopathological, DNA, histological slides, and mRNA expression data were extracted with the GDC Data Transfer Tool. A scree plot was generated to determine the optimal number of clustering groups based on ferroptosis molecular signatures. A K-means clustering approach was used in STATA. Groups of less than 5 patients were excluded. The ferroptosis-based clusters were correlated to clinical, histological, molecular, and survival parameters. Gene Set Enrichment Analysis (GSEA) was also performed by identified cluster. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
175 PDAC cases were used from the TCGA. Optimal K-means clustering identified 4 distinct ferroptosis signature-based PDAC groups, which differed in gene expression. Group 1 (n=47) showed improved overall survival by log-rank analysis versus other 3 groups (p<0.05). There was no significant difference in age, sex distribution, tumor grade, necrosis or staging between Group 1 and other groups. Over-expressed genes in ferroptosis-based group 1 include MAP3K14, TNFAIP3, CYGb; underexpressed genes in Group 1 include EMC2, ZFAS1, CYP4F8. GSEA showed downregulation of EET, DHET and HETE synthesis, and upregulation of RNA metabolism, cell cycle and mitotic activity in Group 1 vs other 3 groups.
Conclusions
A comprehensive multimodal approach to ferroptosis expression signatures highlights a clinical impact on overall survival. However, after post-hoc analysis by two pathologists, no histological marker was identified to be significantly associated with ferroptosis signatures. Genes involved in group 1 modulate nF-κB signaling, target lipid peroxidation, and inhibit GPX4 function. Further ancillary testing of ferroptosis pathway in PDACs is warranted.
Editorial acknowledgement
Legal entity responsible for the study
Vincent Quoc-Huy Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract